The Scientist - Home

WASHINGTON—When Donald Armstrong of the Memorial Sloan-Kettering Cancer Center and his collaborators began to search for compounds that could kill the AIDS virus, they took an increasingly popular approach to the development of anti-viral drugs: they designed their own. Since October the National Institutes of Health have spent or set aside about $25 million for projects like Armstrong‘s that take a targeted approach to developing drugs against AIDS. Most extramural funding for the p

STOCKHOLM—The Swedish government hopes to increase its budget for research and development by $180 million over the next three years. The 3 percent increase will raise its R&D spending, already among the highest in the world at a rate of 2.7 percent of Gross National Product, to $5.7 billion. Nearly one-half of the new money will go into higher education, new research posts and professorships. The government will also push ahead with its controversial plan to compel commercial banks to con

WASHINGTON—More than four months after the Institute of Medicine issued its well-publicized report on AIDS, the disease is still outpacing federal efforts to contain and understand it. "Since the report came out, a lot has happened as far as the epidemic spreading, but very little has been done to implement the strongly felt recommendations of the panel," said June Osborn, dean of the University of Michigan School of Public Health and a member of the group that prepared the report. The nec

WASHINGTON—NIH is cutting research grants to scientists by as much as 20 percent to keep in step with a Reagan budget proposal that is given little chance of being adopted this year by Congress. Lobbying organizations for the biomedical community are preparing to sue the government to halt what they claim is a violation of the wishes of Congress and of the appropriate procedure to achieve such spending reductions. The administration, believing Congress was overly generous to NIH, wants to

PALMERSTON NORTH, N.Z.—A battle is looming over proposed restrictions on research involving in vitro fertilization (IVF) in Australia, a world leader in such studies. The extent of concern among scientists was evident in papers delivered during the annual meeting of the Australian and New Zealand Association for the Advancement of Science (ANZAAS), held here in late January. "In the coming months, the federal Australian parliament may well become an epicenter of biomedical shock," said Rus

Corporate restructurings are forcing some U.S. companies to curtail R&D spending even as they are being urged to increase such investments to remain competitive. Many companies, saddled by the massive debts often involved in such transactions, are having "to change their business strategy from long-term to shorter-term cash flow, which can't help but have an adverse effect on R&D," said Roland W. Schmitt, senior vice president and chief scientist at General Electric and chairman of NSF's Nationa

WASHINGTON—President Reagan's decision to support the construction of a Superconducting Supercollider (SSC) may be the most significant step in its long history. But the January 30 announcement is far from the last word on the subject. A host of unresolved issues remain, from its high price and its uncertain return to its impact on the scientific community in the United States and around the world. Politics is sure to play a major role in choosing the site, including the value of support f

For psychiatrist David A. Hamburg, an early interest in biobehavioral aspects of stress and aggression has broadened to embrace many issues in education, health and public policy. After brief stints at Walter Reed Army Institute of Medical Research and as chief of the adult psychiatry branch at the National Institute of Mental Health, he established the psychiatry department at Stanford University's medical school in 1961. Hamburg left Stan-ford in 1975 to become president of the Institute of Me

WASHINGTON—Financial problems have claimed another victim in the science publishing field. The National Academy of Sciences has decided to fold its quarterly journal, Issues in Science and Technology. "Issues just hasn't been able to attract the audience needed to make it financially successful," said Pepper Leeper, a spokeswoman for the Academy. "It never really broke even," she added, declining to release figures. The 2 ½-year-old journal, aimed at scientists and an informed public,

PALMERSTON NORTH, N.Z.—The head of the major trade union representing scientists and technologists in Britain has denounced "the failure of successive British governments, particularly the present Conservative administration, to provide sufficient funds for science and for R&D, or to take a positive lead in drawing up a national strategy for science." Speaking at the ANZAAS Congress here last month, Clive Jenkins, general secretary of the Association of Scientific, Technical and Managerial

PARIS—The recent decision by the French government to ban for three years any genetic manipulation of the human embryo within the country's leading research centers follows a recommendation from its own expert committee on bioethical questions. The ability to shape public policy has been a hallmark of the committee since it was formed in 1983. Its report, denouncing a "zeal to procreate" among some segments of society, warned that current advances in genetics could be exploited in eugenics

BOSTON—The company that agreed to market the world's first genetically engineered pseudorabies livestock vaccine has charged the vaccine's developer with "fraudulent misrepresentation" of the vaccine's safety and efficacy. According to a claim filed November 13 in U.S. District Court in Houston, TechAmerica Group Inc. would not have entered into its agreement with Novagene Ltd. "had it known the truth with regard to such statements, representations and omissions" in the data presented on t